BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:22UA • US09075V1026

96.85 EUR

-1.2 (-1.22%)

Last: Jan 30, 2026, 07:00 PM

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to 22UA. 22UA was compared to 85 industry peers in the Biotechnology industry. The financial health of 22UA is average, but there are quite some concerns on its profitability. 22UA is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

22UA had negative earnings in the past year.
In the past year 22UA has reported a negative cash flow from operations.
Of the past 5 years 22UA 4 years were profitable.
Of the past 5 years 22UA 4 years had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -2.68%, 22UA is in the better half of the industry, outperforming 65.88% of the companies in the same industry.
The Return On Equity of 22UA (-3.09%) is better than 71.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	-2.68%
ROE	-3.09%
ROIC	N/A

ROA(3y)13.87%

ROA(5y)21.46%

ROE(3y)16.07%

ROE(5y)27.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

22UA has a better Gross Margin (85.62%) than 77.65% of its industry peers.
22UA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for 22UA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	85.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.1%

GM growth 5Y0.34%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 22UA has more shares outstanding
22UA has more shares outstanding than it did 5 years ago.
22UA has a worse debt/assets ratio than last year.

2.2 Solvency

22UA has an Altman-Z score of 6.92. This indicates that 22UA is financially healthy and has little risk of bankruptcy at the moment.
22UA has a better Altman-Z score (6.92) than 82.35% of its industry peers.
22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.01, 22UA is doing good in the industry, outperforming 77.65% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	6.92

ROIC/WACCN/A

WACC7.42%

2.3 Liquidity

22UA has a Current Ratio of 7.12. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.12, 22UA belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
A Quick Ratio of 7.02 indicates that 22UA has no problem at all paying its short term obligations.
The Quick ratio of 22UA (7.02) is better than 88.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.12
Quick Ratio	7.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

22UA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.92%.
22UA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-20.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-114.81%

Revenue 1Y (TTM)3.7%

Revenue growth 3Y-47.47%

Revenue growth 5Y90.73%

Sales Q2Q%22.02%

3.2 Future

Based on estimates for the next years, 22UA will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
Based on estimates for the next years, 22UA will show a small growth in Revenue. The Revenue will grow by 2.25% on average per year.

EPS Next Y-18.87%

EPS Next 2Y-9.18%

EPS Next 3Y-6.05%

EPS Next 5Y7.38%

Revenue Next Year4.7%

Revenue Next 2Y0.06%

Revenue Next 3Y0.94%

Revenue Next 5Y2.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 22UA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 22UA. No positive earnings are expected for the next year.